Clinical Trial Update: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 1/2 study evaluating ribociclib (LEE011) and alpelisib (BYL719) in combination with letrozole for advanced estrogen r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• FEMARA (letrozole)
• KISQALI (ribociclib)
• Piqray (alpelisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING